E. Bischoff

发表

Tumor Prevention by 9-Cis-Retinoic Acid in the N-Nitroso-N-Methylurea Model of Mammary Carcinogenesis is Potentiated by the Pineal Hormone Melatonin

S. Hill, P. Dwivedi, L. Lai, 2002, Breast Cancer Research and Treatment.

Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure.

R. Heyman, W. Lamph, E. Bischoff, 1999, Journal of the National Cancer Institute.

Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin).

W. Lamph, V. Agarwal, E. Bischoff, 2000, Cancer research.

Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5.

T. Rao, A. Shiau, L. Staszewski, 2010, Bioorganic & medicinal chemistry letters.

Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice.

J. Hayes, D. Shalinsky, R. Heyman, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Retinoid-induced suppression of squamous cell differentiation in human oral squamous cell carcinoma xenografts (line 1483) in athymic nude mice.

J. Hayes, M. Gottardis, D. Shalinsky, 1995, Cancer research.

A NovelRetinoicAcidReceptor-selectiveRetinoid , ALRT 155 O , HasPotent Antitumor Activity against Human Oral Squamous Carcinoma Xenografts in Nude Mice '

Marcus, Richard, D. Shalinsky, 2006 .

Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3.

L. Mere, M. Elgort, M. Boehm, 1999, Chemistry & biology.

Macrophage Liver X Receptor Is Required for Antiatherogenic Activity of LXR Agonists

C. Daige, R. Tangirala, R. Heyman, 2004, Arteriosclerosis, thrombosis, and vascular biology.

Development of antiandrogen ARN-509 1 ARN-509 : a novel antiandrogen for prostate cancer treatment

E. Stanchina, H. Scher, V. Arora, 2012 .

Receptor-Ligand LGD 1069 ( Targretin ) with Mammary Tumor Regression by the Retinoid X Induction of Adipocyte-specific Gene Expression Is Correlated Updated

W. Lamph, V. Agarwal, E. Bischoff, 2000 .

Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice.

Andrew C. Li, C. Daige, I. Schulman, 2010, Journal of lipid research.

Development of anti-androgen ARN-509 1 ARN-509: a novel anti-androgen for prostate cancer treatment

H. Scher, V. Arora, C. Sawyers, 2012 .

Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR).

Stefan Westin, Brett R. Murphy, C. Daige, 2009, Journal of medicinal chemistry.

Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.

M. Gottardis, R. Heyman, W. Lamph, 1996, Cancer research.

Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists

L. Hamann, C. Mondon, M. Boehm, 1997, Nature.

ARN-509: a novel antiandrogen for prostate cancer treatment.

H. Scher, V. Arora, C. Sawyers, 2012, Cancer research.

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

K. Walter, Andiliy G. Lai, J. Giltnane, 2016, eLife.

Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.

M. Gottardis, R. Heyman, W. Lamph, 1998, Cancer research.

Identification of macrophage liver X receptors as inhibitors of atherosclerosis

Aldons J. Lusis, Peter Tontonoz, D. Mangelsdorf, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma.

R. Fuchs-Young, C. Walker, K. Burroughs, 2000, The Journal of pharmacology and experimental therapeutics.

Regulation of Cholesterol Homeostasis and Lipid Metabolism in Skeletal Muscle by Liver X Receptors*

G. Muscat, R. Tangirala, I. Schulman, 2002, The Journal of Biological Chemistry.

Promoter-Specific Roles for Liver X Receptor/Corepressor Complexes in the Regulation of ABCA1 and SREBP1 Gene Expression

C. Glass, M. Rosenfeld, S. H. Baek, 2003, Molecular and Cellular Biology.

Farnesoid X Receptor Regulates Bile Acid-Amino Acid Conjugation*

R. Tangirala, I. Schulman, S. Westin, 2003, Journal of Biological Chemistry.

Non-redundant roles for LXRα and LXRβ in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice[S]

Andrew C. Li, C. Daige, I. Schulman, 2010, Journal of Lipid Research.

Efficacy of LGD 1069 ( Targretin ) , a Retinoid X Receptor-Selective Ligand , for Treatment of Uterine Leiomyoma 1

R. Fuchs-Young, C. Walker, K. Burroughs, 2000 .

A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice.

M. Boehm, D. Shalinsky, R. Heyman, 1997, Cancer research.

Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice.

Andrew C. Li, C. Daige, I. Schulman, 2010, Journal of lipid research.

Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5.

T. Rao, A. Shiau, L. Staszewski, 2010, Bioorganic & medicinal chemistry letters.

SAT-341-MET409, an optimized sustained FXR agonist, was safe and well-tolerated in a 14-day phase 1 study in healthy subjects

Kyoung-jin Lee, E. Bischoff, K. Song, 2019, Journal of Hepatology.